News
The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of diffuse midline glioma harboring an ...
Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...
Pharmaceutical Technology on MSN15h
FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy
The US Food and Drug Administration (FDA) has given accelerated approval to Jazz Pharmaceuticals for Modeyso (dordaviprone) ...
Glioma is the most common type of brain cancer in children and younger adults, originating in glial cells and categorized by ...
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive ...
The FDA has granted accelerated approval to dordaviprone for the treatment of diffuse midline glioma with an H3 K27M mutation in patients one year old and older with progressive disease following ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback